About: Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and the United Kingdom. The company's principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the relief of Dementia and Alzheimer's. It is also involved in the preclinical development of Irnicann for the treatment of Glioblastoma Multiforme; and R&D, which focuses on wound management. The company was formerly known as MGC Pharmaceuticals Limited and changed its name to Argent BioPharma Limited. Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Latest price: A$0.03 (+21.43%)
RGT ASX Argent Biopharma Ltd
Argent Biopharma Ltd share price
RGT price activity
Último preço
$ 0,030
Variação (24h)
0,01 AUD (21,43%)
Volume
35K
Volume (média 4 sem.)
-
Abertura
$ 0,03
Variação do dia
$ 0,03 - $ 0,03
Fechamento anterior
$ 0,03
Último negócio
06 Oct, 12:49 am GMT+0
Atrasado
06 Oct, 12:49 am GMT+0
RGT price performance
Atrasado
06 Oct, 12:49 am GMT+0
quote.marketSignals